SI3049413T1 - Polimorf i monofosfatne soli 6-fluoro-2-(-4-(piridin-2-il)but-3-in-1-il)imidazo(1,2a)piridina in njegovih polimorfov kot negativni alosterični modulator receptorja mglu5 - Google Patents
Polimorf i monofosfatne soli 6-fluoro-2-(-4-(piridin-2-il)but-3-in-1-il)imidazo(1,2a)piridina in njegovih polimorfov kot negativni alosterični modulator receptorja mglu5Info
- Publication number
- SI3049413T1 SI3049413T1 SI201431596T SI201431596T SI3049413T1 SI 3049413 T1 SI3049413 T1 SI 3049413T1 SI 201431596 T SI201431596 T SI 201431596T SI 201431596 T SI201431596 T SI 201431596T SI 3049413 T1 SI3049413 T1 SI 3049413T1
- Authority
- SI
- Slovenia
- Prior art keywords
- polymorph
- polymorphs
- imidazo
- pyridin
- fluoro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1317022.0A GB201317022D0 (en) | 2013-09-25 | 2013-09-25 | Polymorphs |
| PCT/EP2014/070492 WO2015044270A1 (en) | 2013-09-25 | 2014-09-25 | Mono-phosphate salt of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2a]pyridine and polymorphs thereof as negative allosteric modulator of mglu5 receptor |
| EP14777052.3A EP3049413B1 (en) | 2013-09-25 | 2014-09-25 | Polymorph i of the mono-phosphate salt of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl] imidazo[1,2a]pyridine and polymorphs thereof as negative allosteric modulator of mglu5 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3049413T1 true SI3049413T1 (sl) | 2020-08-31 |
Family
ID=49553394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201431596T SI3049413T1 (sl) | 2013-09-25 | 2014-09-25 | Polimorf i monofosfatne soli 6-fluoro-2-(-4-(piridin-2-il)but-3-in-1-il)imidazo(1,2a)piridina in njegovih polimorfov kot negativni alosterični modulator receptorja mglu5 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9938270B2 (sl) |
| EP (2) | EP3049413B1 (sl) |
| JP (2) | JP6768504B2 (sl) |
| KR (2) | KR20220088960A (sl) |
| CN (2) | CN105873926A (sl) |
| AU (1) | AU2014327236B2 (sl) |
| CA (1) | CA2925040C (sl) |
| CY (1) | CY1123020T1 (sl) |
| DK (1) | DK3049413T3 (sl) |
| EA (1) | EA028037B1 (sl) |
| ES (1) | ES2794022T3 (sl) |
| GB (1) | GB201317022D0 (sl) |
| HR (1) | HRP20201000T1 (sl) |
| HU (1) | HUE049917T2 (sl) |
| IL (2) | IL293356A (sl) |
| LT (1) | LT3049413T (sl) |
| MX (1) | MX363289B (sl) |
| NZ (1) | NZ719081A (sl) |
| PH (1) | PH12016500546A1 (sl) |
| PL (1) | PL3049413T3 (sl) |
| PT (1) | PT3049413T (sl) |
| RS (1) | RS60478B1 (sl) |
| SG (1) | SG11201602271UA (sl) |
| SI (1) | SI3049413T1 (sl) |
| UA (1) | UA119651C2 (sl) |
| WO (1) | WO2015044270A1 (sl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201317022D0 (en) * | 2013-09-25 | 2013-11-06 | Addex Pharmaceuticals Sa | Polymorphs |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0413605D0 (en) * | 2004-06-17 | 2004-07-21 | Addex Pharmaceuticals Sa | Novel compounds |
| CN101568531B (zh) * | 2006-12-21 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | Mglur5受体拮抗剂的多晶型物 |
| GB201204962D0 (en) * | 2012-03-21 | 2012-05-02 | Addex Pharmaceuticals Sa | Pharmaceutical combination products for parkinsons disease |
| GB201210530D0 (en) * | 2012-06-13 | 2012-07-25 | Addex Pharmaceuticals Sa | Extended release formulations |
| GB201317022D0 (en) * | 2013-09-25 | 2013-11-06 | Addex Pharmaceuticals Sa | Polymorphs |
-
2013
- 2013-09-25 GB GBGB1317022.0A patent/GB201317022D0/en not_active Ceased
-
2014
- 2014-09-25 AU AU2014327236A patent/AU2014327236B2/en active Active
- 2014-09-25 WO PCT/EP2014/070492 patent/WO2015044270A1/en active Application Filing
- 2014-09-25 NZ NZ719081A patent/NZ719081A/en unknown
- 2014-09-25 CA CA2925040A patent/CA2925040C/en active Active
- 2014-09-25 HU HUE14777052A patent/HUE049917T2/hu unknown
- 2014-09-25 KR KR1020227020933A patent/KR20220088960A/ko not_active Application Discontinuation
- 2014-09-25 ES ES14777052T patent/ES2794022T3/es active Active
- 2014-09-25 US US15/023,764 patent/US9938270B2/en active Active
- 2014-09-25 MX MX2016003816A patent/MX363289B/es unknown
- 2014-09-25 CN CN201480058742.8A patent/CN105873926A/zh active Pending
- 2014-09-25 EP EP14777052.3A patent/EP3049413B1/en active Active
- 2014-09-25 CN CN202010267173.5A patent/CN111574516A/zh active Pending
- 2014-09-25 EP EP20166777.1A patent/EP3693370A1/en not_active Withdrawn
- 2014-09-25 PT PT147770523T patent/PT3049413T/pt unknown
- 2014-09-25 RS RS20200750A patent/RS60478B1/sr unknown
- 2014-09-25 UA UAA201604307A patent/UA119651C2/uk unknown
- 2014-09-25 KR KR1020167010700A patent/KR102412602B1/ko active IP Right Grant
- 2014-09-25 EA EA201690616A patent/EA028037B1/ru unknown
- 2014-09-25 SI SI201431596T patent/SI3049413T1/sl unknown
- 2014-09-25 IL IL293356A patent/IL293356A/en unknown
- 2014-09-25 SG SG11201602271UA patent/SG11201602271UA/en unknown
- 2014-09-25 DK DK14777052.3T patent/DK3049413T3/da active
- 2014-09-25 LT LTEP14777052.3T patent/LT3049413T/lt unknown
- 2014-09-25 PL PL14777052T patent/PL3049413T3/pl unknown
- 2014-09-25 JP JP2016516897A patent/JP6768504B2/ja active Active
- 2014-09-25 IL IL244673A patent/IL244673B/en unknown
-
2016
- 2016-03-22 PH PH12016500546A patent/PH12016500546A1/en unknown
-
2020
- 2020-06-03 CY CY20201100501T patent/CY1123020T1/el unknown
- 2020-06-25 HR HRP20201000TT patent/HRP20201000T1/hr unknown
- 2020-07-01 JP JP2020114466A patent/JP2020172512A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263404B (en) | History of ring-fused bicyclic pyridyls as fgfr4 inhibitors | |
| IL246474A0 (en) | Heteroaryl substituted nicotinamide compounds | |
| EP3025414A4 (en) | Double-sided lcc compensation method for wireless power transfer | |
| ZA201506747B (en) | Imidazo pyridine compounds | |
| HK1221465A1 (zh) | 新型雜環化合物 | |
| SG11201403910QA (en) | System for controlling the temperature of subsea equipment | |
| ZA201507657B (en) | Pyridin-4-yl derivatives | |
| IL245443A0 (en) | Disubstituted pyridine derivatives are useful as gsk–3 inhibitors | |
| IL241758B (en) | Preparation of pyrimidine intermediates useful for the manufacture of macitentan | |
| ZA201701755B (en) | Fused heterocyclic compounds as gpr120 agonists | |
| SG11201509511QA (en) | Five-membered heterocyclic pyridine compounds and preparation method and use thereof | |
| SI3049413T1 (sl) | Polimorf i monofosfatne soli 6-fluoro-2-(-4-(piridin-2-il)but-3-in-1-il)imidazo(1,2a)piridina in njegovih polimorfov kot negativni alosterični modulator receptorja mglu5 | |
| IL245918B (en) | Dialkyl(oxido)-4 lamda-sulfanylidine nicotinamide derivatives as kinase inhibitors | |
| IL243133B (en) | Method for the preparation of (1,2,4)-triazolo(4,3-a)pyridines | |
| IL239228A0 (en) | Improved process for the preparation of n-cyano-s-[1-(pyridine-3-yl)ethyl]-s-methylsulfylamines | |
| HK1213554A1 (zh) | 用於製備硼酸中間體的方法 | |
| TH1401007032A (th) | การสังเคราะห์ไพร์โรโล [2,3-b] ไพริดีน | |
| AU2014901169A0 (en) | Heterocyclic compounds for blood glucose regulation |